Astronomy meets pathology to identify predictive biomarkers for cancer immunotherapy


Sumary of Astronomy meets pathology to identify predictive biomarkers for cancer immunotherapy:

  • A new platform, called AstroPath, melds astronomic image analysis and mapping with pathology specimens to analyze microscopic images of tumors..
  • Immunofluorescent imaging, using antibodies with fluorescent tags, enables researchers to visualize multiple cellular proteins simultaneously and determine their pattern and strength of expression..
  • PD-1 (programmed cell death 1) is a protein found on immune system T cells which, when bound to another protein called PD-L1 (programmed death ligand), helps cancer cells evade attack by the immune system..
  • Only some patients with melanoma respond to anti-PD-1 therapy, and the ability to predict response or resistance is critical to choosing the best treatments for each patient’s cancer, the researchers explain..
  • The AstroPath platform is also being applied to study in lung cancer and potentially can provide therapeutic guidance for many other cancers..
  • “For the last 40 years, pathology analysis of cancer has examined one marker at a time, which provides limited information..
  • Leveraging new technology, including instrumentation to image up to 12 markers simultaneously, the AstroPath imaging algorithms provide 1,000 times the information content from a single biopsy than is currently available through routine pathology..
  • This facilates precision cancer immunotherapy — identifying the unique features of each patient’s cancer to predict who will respond to a given immunotherapy, such as anti-PD-1, and who will not….

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.